The global cell lysis & disruption market was valued at USD 4.02 billion in 2020 and is expected to grow at a CAGR of 9.3% during the forecast period. The growing number of R&D activities for the development of personalized medicines leads to cell lysis & disruption growth. Also, rising government initiatives and funding for the innovation of the proficient COVID-19 vaccine are attributed to the lysis & disruption systems market growth.
Know more about this report: request for sample pages
Furthermore, increasing demand for effective tumor tissue dissociation equipment impels the advancements of the new products based on microfluidics, further boosting the cell lysis & disruption market demand across the globe. The widespread COVID-19 pandemic has positively impacted the cellular disruption systems market due to the rising need for critical medical solutions and diagnostic kits.
The increasing number of R&D activities to develop COVID-19 vaccines boosts the demand for the technologies implemented in the bio-processing, which also comprises cell lysis & disruption. As a result, organizations are changing their target to providing bioprocessing-related solutions in the lysis & disruption systems market. Therefore, the rapid development of healthcare facilities and therapeutics during this period is exhibiting an upsurge in the global lysis & disruption systems market demand.
These technologies are used in the effective release of compounds consistently, competently, and effectively. Also, it improves potential developments; thereby, it is driving the lysis & disruption systems industry growth throughout the world. Furthermore, the increasing adoption of the instruments also provides a high yield and can lyse cells, are trouble-free for cleaning, assure scalability as well as maximize active compound. Several widespread instruments such as the polytron homogenizer and blender are beneficial in an unsettling large amount of yeast samples and take out proteins from huge quantities of mammalian compound tissue.
Numerous instrument companies are developing a wide range of instruments to carry out cell lysis procedures in the cell lysis & disruption market. Consequently, all these benefits lead to the demand for the instruments used in the process of cell lysis, which, in turn, accelerate the lysis & disruption systems market growth in the upcoming period. Various government organizations support in the form of by raising funds, investments, and providing grants.
The market is primarily segmented on the basis of technique, product, application, end-use and region.
Know more about this report: request for sample pages
The protein isolation segment is expected to hold the highest revenue share over the forecast period. The rising need for proficient and quick lysis techniques can extort the proteins with the least oxidation and protein breakdown. Moreover, innovations in the highly developed bioprocessing equipment and reagents propel the segment growth. Therefore, these benefits offered by protein isolation lead to the dominance of the segment in the cellular disruption systems market. The downstream processing segment is projected to show the fastest growth rate in the upcoming years.
The growing demand for industrial biotechnology goods such as antibiotics, antibodies, vaccines, hormones, and enzymes is fueling the lysis & disruption systems market. Moreover, the ongoing efforts to develop vaccines for preventing coronavirus spread are also acting as a catalyzing factor for the segment demand. Accordingly, these are some prominent factors that fuel the segment growth in the upcoming years.
The Pharmaceuticals & biotechnology companies segment had the highest revenue share in the global lysis & disruption systems market in 2020. The growing presence of the leading volume of the biotechnology companies, which discover the bioprocess techniques and molecular biology by utilizing lysis protocols. The efficiency and safety presented by biopharmaceuticals products and the capability to handle clinical conditions that were not cured previously are propelling the cell lysis & disruption market growth.
As a result, Pharmaceuticals organizations are rapidly moving towards developing biopharmaceuticals products, which, in turn, leads to segment dominance. The cell banking segment is projected to show the highest CAGR in the foreseen years. The various protocols for tumorigenicity research and testing have attributed to the considerable adoption of cell disruption methods across the biospecimen banking services and facilities.
Furthermore, the medical clinical study carried out for drug development is driving the potential growth in the forecasting period. Thus, these factors lead to segment growth in the estimated year.
Geographically, North America is leading the lysis & disruption systems market with the highest revenue share in 2020. The government's growing focus on supporting cancer research, molecular biology research, and evolving precision medicines are the factors that lead to the dominance of the regional cellular disruption market. Furthermore, increasing R&D activities in the healthcare sector to discover novel drugs patterns and medicines for treating rare diseases or health problems are likely to stimulate the lysis & disruption systems market demand across North America.
Asia Pacific is projected to show a significant CAGR in the forecasting years. The increasing number of players in the lysis & disruption systems market and the fast acceptance of technological innovation, mainly in countries like Japan and China, boosts the lysis & disruption systems market growth. In addition, the government also takes the initiative for the market development. The rapid growth of the personalized therapeutics for cancer treatment further contributes to the development of the regional market. Therefore, these factors fosters the lysis & disruption systems market growth in Asia Pacific in the upcoming scenario.
Major market players include Becton Dickinson & Company (BD), Bio-Rad Laboratories, BioVision, Inc., Cell Signaling Technology Inc., Claremont BioSolutions, LLC, Covaris, Danaher Corp., Roche Molecular Systems, Inc., Geno Technology Inc., Merck KGaA, Microfluidics International Corp., Miltenyi Biotec, Norgen Biotek Corp., NZYTech Lda, Parr Instrument Company, PromoCell GmbH, Qsonica LLC, STEMCELL Technologies Inc., and Thermo Fisher Scientific.
Market size value in 2020
USD 4.02 billion
Revenue forecast in 2028
USD 7.95 billion
9.3% from 2021 - 2028
2016 - 2019
2021 - 2028
Revenue in USD billion and CAGR from 2021 to 2028
By Technique, By Product, By Application, By End-Use, By Region
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Becton Dickinson & Company (BD), Bio-Rad Laboratories, BioVision, Inc., Cell Signaling Technology Inc., Claremont BioSolutions, LLC, Covaris, Danaher Corp., Roche Molecular Systems, Inc., Geno Technology Inc., Merck KGaA, Microfluidics International Corp., Miltenyi Biotec, Norgen Biotek Corp., NZYTech Lda, Parr Instrument Company, PromoCell GmbH, Qsonica LLC, STEMCELL Technologies Inc., and Thermo Fisher Scientific.